InnovaVector

Executive Summary

InnovaVector is an Italian CDMO specializing in adeno-associated viral (AAV) vectors for gene and cell therapies. Founded in 2020 as a spin-off from the Telethon Institute of Genetics and Medicine (TIGEM), the company leverages over two decades of foundational IP and expertise to offer end-to-end services from discovery research through GMP manufacturing. Based in Milan, InnovaVector supports clients in preclinical development and clinical trials, addressing the growing demand for high-quality AAV vectors in the gene therapy market. The company's deep technical roots and focus on AAV positions it as a reliable partner for biotech and pharma companies seeking to advance gene therapies. The gene therapy CDMO market is expanding rapidly, driven by increasing pipeline activity and regulatory approvals. InnovaVector differentiates itself through its proprietary AAV vector platform and experienced team from TIGEM. However, as a relatively young private company, it faces competition from established CDMOs. Near-term growth will depend on securing new client contracts, expanding manufacturing capacity, and achieving key certifications. With a solid foundation and strategic focus, InnovaVector is well-positioned to capture market share, though execution risks remain typical for early-stage CDMOs.

Upcoming Catalysts (preview)

• Q3 2026New Client Partnership or License Agreement70% success
• Q4 2026Completion of GMP Manufacturing Suite Expansion80% success
• Q3 2026Obtainment of ISO or GMP Certification60% success